Cargando…

Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models

[Image: see text] The first kinase inhibitor drug approval in 2001 initiated a remarkable decade of tyrosine kinase inhibitor drugs for oncology indications, but a void exists for serine/threonine protein kinase inhibitor drugs and central nervous system indications. Stress kinases are of special in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Saktimayee M., Grum-Tokars, Valerie L., Schavocky, James P., Saeed, Faisal, Staniszewski, Agnieszka, Teich, Andrew F., Arancio, Ottavio, Bachstetter, Adam D., Webster, Scott J., Van Eldik, Linda J., Minasov, George, Anderson, Wayne F., Pelletier, Jeffrey C., Watterson, D. Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2015
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404319/ https://www.ncbi.nlm.nih.gov/pubmed/25676389 http://dx.doi.org/10.1021/acschemneuro.5b00002

Ejemplares similares

Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic Dysfunction
por: Watterson, D. Martin, et al.
Publicado: (2013)

A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction
por: Roy, Saktimayee M., et al.
Publicado: (2019)

Correction to “A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction”
por: Roy, Saktimayee M., et al.
Publicado: (2020)

Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology
por: Maphis, Nicole, et al.
Publicado: (2016)

Involvement of p38 MAPK in Synaptic Function and Dysfunction
por: Falcicchia, Chiara, et al.
Publicado: (2020)

Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
por: Zhou, Zhengqiu, et al.
Publicado: (2017)

Target Engagement Analysis and Link to Pharmacodynamic Endpoint for a Novel Class of CNS-penetrant and Efficacious p38α MAPK Inhibitors
por: Bachstetter, Adam D., et al.
Publicado: (2014)

Inhibition of Neuronal p38α, but not p38β MAPK, Provides Neuroprotection Against Three Different Neurotoxic Insults
por: Xing, Bin, et al.
Publicado: (2014)

A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model
por: Munoz, Lenka, et al.
Publicado: (2007)

Microglial p38α MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Aβ)
por: Bachstetter, Adam D, et al.
Publicado: (2011)

Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα
por: Xing, Bin, et al.
Publicado: (2011)

PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease
por: Teich, Andrew F., et al.
Publicado: (2016)

Deficiency in p38β MAPK Fails to Inhibit Cytokine Production or Protect Neurons against Inflammatory Insult in In Vitro and In Vivo Mouse Models
por: Xing, Bin, et al.
Publicado: (2013)

Dynamin 1 Is Required for Memory Formation
por: Fà, Mauro, et al.
Publicado: (2014)

A Reliable Way to Detect Endogenous Murine β-Amyloid
por: Teich, Andrew F., et al.
Publicado: (2013)

Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer's disease
por: Lee, Linda, et al.
Publicado: (2014)

Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse
por: Teich, Andrew F., et al.
Publicado: (2018)

Corrigendum: Regulation of synaptic plasticity and cognition by SUMO in normal physiology and Alzheimer’s disease
por: Lee, Linda, et al.
Publicado: (2015)

p38δ MAPK: Emerging Roles of a Neglected Isoform
por: O'Callaghan, Carol, et al.
Publicado: (2014)

Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease
por: Webster, Scott J, et al.
Publicado: (2013)

Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic
por: Bachstetter, Adam D, et al.
Publicado: (2015)

Generation and Behavior Characterization of CaMKIIβ Knockout Mice
por: Bachstetter, Adam D., et al.
Publicado: (2014)

The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism
por: Bachstetter, Adam D, et al.
Publicado: (2014)

Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice
por: Gnanaprakash, Madhumathi, et al.
Publicado: (2021)

Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models
por: Webster, Scott J., et al.
Publicado: (2014)

Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology
por: Braun, David J., et al.
Publicado: (2022)

The p38α mitogen-activated protein kinase as a central nervous system drug discovery target
por: Borders, Aaron S, et al.
Publicado: (2008)

Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery
por: Grum-Tokars, Valerie, et al.
Publicado: (2008)

Genetic knockout of myosin light chain kinase (MLCK210) prevents cerebral microhemorrhages and attenuates neuroinflammation in a mouse model of vascular cognitive impairment and dementia
por: Braun, David J., et al.
Publicado: (2019)

p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse
por: Robson, Matthew J., et al.
Publicado: (2018)

Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer’s disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid
por: Asam, Kesava, et al.
Publicado: (2017)

p38 MAPK in MDS
por: Gañán‐Gómez, Irene, et al.
Publicado: (2015)

Deletion of p38α MAPK in microglia blunts trauma-induced inflammatory responses in mice
por: Morganti, Josh M., et al.
Publicado: (2019)

Clinically relevant intronic splicing enhancer mutation in myelin proteolipid protein leads to progressive microglia and astrocyte activation in white and gray matter regions of the brain
por: Bachstetter, Adam D, et al.
Publicado: (2013)

p38 MAPK Pathway in the Heart: New Insights in Health and Disease
por: Romero-Becerra, Rafael, et al.
Publicado: (2020)

p38γ MAPK Inflammatory and Metabolic Signaling in Physiology and Disease
por: Qi, Xiao-Mei, et al.
Publicado: (2023)

p38 MAPK in cardioprotection – are we there yet?
por: Martin, E D, et al.
Publicado: (2015)

Time-dependent reversal of synaptic plasticity induced by physiological concentrations of oligomeric Aβ42: an early index of Alzheimer’s disease
por: Koppensteiner, Peter, et al.
Publicado: (2016)

A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease
por: Luo, Jia, et al.
Publicado: (2016)

Erratum to: A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer’s disease
por: Luo, Jia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k8n7iv6tb6372mqqnkj2ljc5qu